证券研究报告 | 2026年03月06日 策略周报 全国两会召开，积极基调延续——每周海内外重要政策跟踪 国内宏观：2 月 27 日，中共中央政治局召开会议，强调实施更加积极的财政 政策和适度宽松的货币政策；同日，证监会发布《私募投资基金信息披露监 督管理办法》，自 2026 年 9 月 1 日起施行。3 月 2 日，国家税务总局发布服 务全国统一大市场建设六项举措成果；同日，科技部等四部门联合发布《关 于加快推动科技保险高质量发展有力支撑高水平科技自立自强的若干意见》， 提出 20 项政策举措；同日，国家发改委主任郑栅洁主持召开民营企业座谈 会，明确将持续深化与民营企业常态化沟通，促进民营经济高质量发展。3 月 4 日，财政部等三部门发布"十五五"期间中西部地区国际性展会进口展 品税收优惠政策，免征相关税费并扩大优惠范围。3 月 5 日，十四届全国人 大四次会议开幕，李强总理在政府工作报告中提出，今年经济增长目标为 4.5%-5%，并就建设强大国内市场、加紧培育壮大新动能、加快高水平自立 自强等做出部署。 产业政策：2 月 27 日，中国载人航天工程办公室明确 2026 年将深化推进空 间站应用与发展和载人 ...

记者近日从市场监管总局食品审评中心获悉：特殊医学用途配方食品国产注册占比从2020年的49% 增至2025年的88%。肿瘤全营养配方、增稠组件等以往依赖进口的品类陆续转为国产注册上市，市场规 模从2020年的70亿元增至2024年的230亿元，年均复合增长率超过25%。 2025年批准适用于甲基丙二酸血症（发病率不足十万分之一）等罕见病患儿的特医食品注册上市， 实现该领域国产产品零的突破，切实保障小众特殊群体"生命口粮"。截至目前，我国已有293款特医食 品产品注册上市。 ...

人民日报北京2月23日电 记者近日从市场监管总局食品审评中心获悉：特殊医学用途配方食品国产注册 占比从2020年的49%增至2025年的88%。肿瘤全营养配方、增稠组件等以往依赖进口的品类陆续转为国 产注册上市，市场规模从2020年的70亿元增至2024年的230亿元，年均复合增长率超过25%。 2025年批准适用于甲基丙二酸血症（发病率不足十万分之一）等罕见病患儿的特医食品注册上市，实现 该领域国产产品零的突破，切实保障小众特殊群体"生命口粮"。截至目前，我国已有293款特医食品产 品注册上市。（记者林丽鹂） ...

Core Insights - The establishment of the Shaanxi Provincial Quality Supervision and Inspection Research Institute's high-tech laboratory in the Qinhan Health Industry Park marks a significant step in creating a leading health industry innovation hub in Western China [1][2] - The collaboration between Qinhan New City and the Shaanxi Provincial Market Supervision Administration aims to enhance the quality support of the health industry chain and improve the competitiveness and safety levels of the health industry in Shaanxi Province [2] Group 1 - The high-tech laboratory's entry signifies a new phase in the cooperation between the Shaanxi Provincial Quality Supervision Institute and local authorities, focusing on building a national-level health product quality inspection center and various innovation platforms [1] - The upcoming relocation of additional laboratories from the Shaanxi Provincial Quality Supervision Institute will lead to the establishment of two national-level centers, which will provide comprehensive inspection, quality evaluation, and technical research services in cutting-edge fields such as biomedicine and high-end medical devices [1] Group 2 - The integration of provincial quality inspection resources in the Qinhan Health Industry Park is crucial for bridging the gap in result transformation and enhancing the overall health industry ecosystem [2] - The presence of the Shaanxi Provincial Quality Supervision Institute is expected to attract high-quality enterprises, accelerate talent aggregation, and support the integrated model of "construction, operation, and management" within the park [2] - The ongoing construction of key projects, including the National Emergency Medical Rescue Base and a flagship hospital for integrated Chinese and Western medicine, will further enhance the health industry chain in the region [2]

Core Viewpoint - The implementation plan aims to enhance the adaptability of supply and demand in consumer goods, promoting consumption upgrades to lead industrial upgrades and achieving a dynamic balance between supply and demand [1][3] Group 1: Key Areas of Focus - The plan outlines 19 key tasks across five areas, focusing on industries such as smart connected vehicles, smart home products, consumer electronics, modern textiles, food, and green building materials [1] - It emphasizes the development of innovative applications and the creation of flagship products and enterprises, along with establishing testing platforms in various consumer goods sectors [1] Group 2: Expanding Product Supply - The plan advocates for the development of leisure and sports products, targeting new demands from event economies and outdoor activities, and promoting high-quality sports equipment [2] - It aims to diversify product offerings for specific demographics, including children's products, quality student supplies, trendy items, and age-appropriate products [2] Group 3: Innovation and Internal Demand Activation - By 2027, the plan targets a significant optimization of the consumer goods supply structure, aiming to create three trillion-level consumption fields and ten hundred-billion-level consumption hotspots [3] - The policy is expected to positively impact various industries, including smart vehicles, home products, and health-related goods, by fostering technological innovation and responding to new market demands [3][4] Group 4: Focus on Specific Demographics - The policy particularly addresses the needs of specific consumer groups, promoting the refinement and quality enhancement of products for children, students, and the elderly [4] - New consumption formats such as live e-commerce and instant retail are expected to develop in an orderly manner, injecting vitality into core business districts and new product launches [4]

Core Viewpoint - The implementation plan aims to enhance the adaptability of supply and demand in consumer goods, promoting consumption upgrades to lead industrial upgrades and achieving a dynamic balance between supply and demand [1][2]. Group 1: Key Areas of Focus - The plan outlines 19 key tasks across five areas, focusing on industries such as smart connected vehicles, smart home products, consumer electronics, modern textiles, food, and green building materials [1]. - It emphasizes the development of leisure and sports products, targeting new demands from event economies, outdoor economies, and winter sports, while promoting high-quality sports equipment [1][2]. Group 2: Targeted Consumer Needs - The plan aims to match diverse consumer needs by enriching the supply of baby products, enhancing quality student supplies, expanding trendy products, and optimizing products for the elderly [2][3]. - It also seeks to cultivate new consumption scenarios and business models, including the promotion of product launches, orderly development of platform consumption, and regulated shared consumption [2]. Group 3: Future Goals - By 2027, the plan targets a significant optimization of the consumer goods supply structure, aiming to create three trillion-level consumption fields and ten hundred-billion-level consumption hotspots [2]. - By 2030, it envisions a high-quality development pattern where supply and consumption interact positively, with a steady increase in consumption's contribution to economic growth [2]. Group 4: Industry Impact - The implementation of the plan is expected to positively impact multiple industries, including smart connected vehicles, smart home products, consumer electronics, and green building materials, driving technological innovation through the creation of flagship products and innovative application scenarios [2][3]. - The sports and leisure product sectors are anticipated to benefit from new demands arising from event and outdoor economies, gaining new growth momentum [2].

Core Viewpoint - The State Administration for Market Regulation (SAMR) is revising the production licensing review guidelines for special medical purpose formula foods, aiming to enhance the classification and safety management of these products for specific patient groups [1][2]. Group 1: Product Classification - The new guidelines significantly refine product categories, increasing the number of types from 27 to 46 [2]. - Full nutritional formula foods are now categorized based on age groups: suitable for ages 1 to 10, suitable for ages over 10, and specific nutritional adjustment formulas [4]. Group 2: Targeted Nutrition - The revised guidelines allow for more targeted selection of special medical purpose foods based on individual diseases and conditions, under medical guidance [6]. Group 3: Regulatory Oversight - SAMR has approved 236 products from 71 domestic companies and 32 products from 14 foreign companies [7]. - The new guidelines impose stricter requirements on raw material safety and key production process monitoring, ensuring higher safety standards compared to regular food products [8]. Group 4: Raw Material Management - Companies must establish monitoring mechanisms for risk substances in raw materials and ensure compliance with national standards during transportation [8]. - There are specific requirements for the inspection of raw materials, particularly those containing milk, to prevent contamination [10]. Group 5: Equipment and Hygiene Monitoring - The guidelines require production companies to equip critical machinery with operational monitoring and fault alarm functions to ensure compliance with technical requirements [12][13]. - Companies must implement hygiene monitoring systems for production environments, personnel, and equipment [10]. Group 6: Allergen Control - The new guidelines specify measures to manage allergenic substances during production, including the segregation of raw materials that contain allergens [14][16]. - Enhanced requirements for companies producing special medical foods to prevent cross-contamination with allergenic materials have been established [16].

Investment Rating - The report indicates a positive outlook for the special medical purpose formula food industry, driven by policy support and clinical demand, suggesting a potential for rapid market expansion [3][10]. Core Insights - Special medical purpose formula foods (medical foods) are designed to meet the nutritional needs of specific populations and must be consumed under medical supervision. The market is expected to grow significantly due to increasing product diversity, enhanced policy support, and improved clinical nutrition practices [3][4][10]. - The industry is characterized by a growing number of approved products, a significant advantage for domestic brands, and a diverse range of entering companies [11][12][40]. Summary by Sections Industry Overview - Special medical purpose formula foods cater to individuals with restricted diets, absorption disorders, or specific medical conditions, and are becoming a vital part of treatment strategies for various diseases in China [4][6]. - The market currently has a low penetration rate due to insufficient awareness and regulatory standards, but it is poised for growth as recognition and product availability increase [32][33]. Regulatory Environment - The "Special Medical Purpose Formula Food Registration Management Measures (2024)" aims to standardize registration processes, ensuring product quality and safety while encouraging innovation [9][10][39]. - As of September 30, 2024, a total of 206 special medical foods have been registered, with 174 being domestic products, indicating a strong growth trend for local brands [11][12]. Market Dynamics - The industry is witnessing a diversification of companies entering the market, with 58 companies having obtained registration, and Nestlé leading in the number of approved products [12][40]. - The distribution channels for medical foods face challenges, particularly in offline retail, where awareness and proper categorization are lacking. However, online sales are expected to grow as regulations become clearer [22][33]. Product Analysis - Among the registered products, 58 are special medical infant formula foods, accounting for 28.2% of the total, while 82 are non-full nutritional formula foods, and 65 are full nutritional formula foods [21]. - The report highlights a trend towards convenience in product forms, with a majority being powder-based [11]. Competitive Landscape - The competitive landscape shows that domestic products outnumber imports, but there is a noted lack of product diversity among local companies, which may impact future growth [40][41]. - Companies are encouraged to pursue differentiated product strategies to enhance their market positions, with a focus on both infant and non-infant medical foods [42].

Core Viewpoint - Saintong Special Medical (Qingdao) Nutrition Health Technology Co., Ltd. is preparing for an IPO in Hong Kong, backed by the dairy giant Shengyuan Group, and is positioned as a leading player in the special medical food market for infants in China, with a projected revenue CAGR of 30.3% from 2022 to 2024 [1][5]. Group 1: Company Overview - Saintong Special Medical was established in 2019, evolving from Shengyuan Group's special medical division, and has received investments from notable institutions such as Honghui Fund and Hillhouse Capital [5]. - The company holds the most infant special medical food registration certificates in China and aims to leverage this advantage in the market [1][11]. Group 2: Market Position and Financial Performance - In 2024, Saintong is projected to capture 9.5% of the infant special medical food market, ranking third in the industry, while two foreign giants dominate with a combined market share of approximately 75% [3][9]. - Revenue is expected to grow from RMB 491.2 million in 2022 to RMB 834.1 million in 2024, with a gross margin consistently above 71% [4][25]. Group 3: Sales and Distribution Challenges - Despite strong revenue growth, the brand's presence in major retail outlets is limited, with reports indicating that many stores do not carry its products [3][15]. - The company's online sales are significantly lower compared to competitors, with historical sales of only 2,000 units for a key product, compared to over 70,000 units for a rival brand [13][15]. Group 4: Financial Concerns - The company has seen a dramatic increase in inventory turnover days, rising 187% to 155 days over three years, which raises questions about inventory management [19][20]. - Saintong's net current liabilities exceeded RMB 400 million in 2024, yet the company has maintained high dividend payouts, raising concerns about financial sustainability [22][23]. Group 5: Research and Development - R&D expenditures have remained below 2% of revenue, which is significantly lower than industry standards, potentially hindering innovation and competitiveness [32][35]. - The company has launched 14 major special medical food products and has 16 more in development, indicating a commitment to expanding its product line [11][28].

Core Viewpoint - The first listed company in the special medical purpose formula food sector in China is expected to emerge, with Saintong Special Medical (Qingdao) Nutrition and Health Technology Co., Ltd. filing for an IPO in Hong Kong [1] Group 1: Market Position and Competition - Saintong Special Medical holds a 6.3% market share, ranking fourth in the Chinese market, and is the only domestic brand among the top five [2] - The company has achieved a breakthrough with two special medical foods for rare diseases approved in early 2025, marking a significant milestone for domestic brands [2] - The competition in the special medical food sector is intensifying as more formulas are approved, posing a challenge for Saintong Special Medical to maintain its competitive edge [2][12] Group 2: Regulatory Environment and Industry Development - The approval of the Special Medical Purpose Formula Food Registration Management Measures in 2016 initiated a period of standardized development for the industry [3] - The high entry barriers due to stringent registration requirements and long approval cycles (1-3 years) create a challenging environment for new entrants [3] Group 3: Product Portfolio and Financial Performance - Saintong Special Medical holds six infant special medical food registration certificates, the highest among domestic brands [4] - The company achieved revenue of 834 million yuan in 2024, with a compound annual growth rate of 30.3% over the past three years [5] - The average selling price of the allergy prevention product series is 332 yuan per kilogram, with a gross margin of 72%, significantly higher than that of its discontinued non-special medical milk powder [5] - The adjusted net profit for 2024 is close to 200 million yuan, with an adjusted net profit margin of 23.9%, surpassing that of high-end milk powder brands like Feihe [5] Group 4: Production and Operational Efficiency - Approximately 40% of the company's products have yet to complete domestic registration [6] - The company has outsourced production to its controlling shareholder's subsidiary in South Korea, optimizing capital return efficiency [7] - The return on equity (ROE) reached an impressive 75% after excluding the impact of financial liabilities [8] - The adjusted asset-liability ratio is 1.6% in 2024, with minimal leasing liabilities and bank loans [11] Group 5: Future Growth and Strategic Direction - The special medical food market is still considered a niche sector, with a total market size of 23.2 billion yuan in 2024, and the infant special medical food market reaching 13.5 billion yuan [26] - Saintong Special Medical plans to shift its focus towards non-infant special medical foods, aiming to commercialize 12 new products within five years [27] - The company is developing specific full-nutrition formula foods for diseases, with a longer registration cycle of 3-5 years due to stricter standards [29][30] - The increasing approval speed of formulas is expected to heighten competition in the sector [32]